Brainsway Ltd
TASE:BWAY
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
937.1
2 026
|
Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Brainsway Ltd
Common Stock
Brainsway Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
B
|
Brainsway Ltd
TASE:BWAY
|
Common Stock
$367k
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
Nano-X Imaging Ltd
NASDAQ:NNOX
|
Common Stock
$165k
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
||
Inmode Ltd
NASDAQ:INMD
|
Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Sisram Medical Ltd
HKEX:1696
|
Common Stock
$1.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
||
S
|
Sofwave Medical Ltd
TASE:SOFW
|
Common Stock
$66.9m
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
E
|
Epitomee Medical Ltd
TASE:EPIT
|
Common Stock
$90.2m
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Brainsway Ltd
Glance View
Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
See Also
What is Brainsway Ltd's Common Stock?
Common Stock
367k
USD
Based on the financial report for Dec 31, 2023, Brainsway Ltd's Common Stock amounts to 367k USD.
What is Brainsway Ltd's Common Stock growth rate?
Common Stock CAGR 10Y
9%
Over the last year, the Common Stock growth was 2%. The average annual Common Stock growth rates for Brainsway Ltd have been 17% over the past three years , 17% over the past five years , and 9% over the past ten years .